Parathyroidectomy: Single Gland vs Multi-gland Surgery

Primary hyperparathyroidism (PHPT) — autonomous PTH (parathyroid hormone) hypersecretion by parathyroid glands (usually 4 — upper and lower pairs, behind thyroid); resulting in hypercalcaemia + hypophosphataemia + increased bone turnover. Adult prevalence 0.1-0.3%; women 2-3× more; peak 40-60 years.

Aetiology: (1) single adenoma (85%) — benign tumour in one parathyroid, autonomous PTH; (2) multi-gland hyperplasia (15%) — all four glands proliferate, often familial (MEN-1, MEN-2A, familial isolated hyperparathyroidism); (3) double adenoma (rare, 2-5%) — true vs asymmetric hyperplasia debated; (4) parathyroid carcinoma (1%) — aggressive malignancy.

Classical "stones, bones, abdominal moans, psychic groans": (1) renal stones (calcium oxalate — 20-30%), nephrocalcinosis; (2) bone loss — osteopenia, osteoporosis, pathological fracture, "subperiosteal resorption" (phalanx); (3) abdominal — peptic ulcer, pancreatitis, constipation, nausea/vomiting; (4) psychic — depression, anxiety, concentration difficulty, fatigue, memory issues.

Modern picture: severe symptomatic disease now rare — most diagnosed on routine biochemistry ("asymptomatic hyperparathyroidism"). Mild hypercalcaemia (11-12 mg/dL), normal/high PTH, hypercalciuria often initial finding. Complaints insidious (fatigue, bone pain, mild depression) — may be missed.

Other aetiologies: secondary hyperparathyroidism (CKD, vitamin D deficiency, malabsorption — chronic low calcium drives PTH), tertiary (long-standing secondary leading to autonomous glands — persistent post-transplant). Different management.

Family history and syndromic workup: MEN-1 (parathyroid + pancreas + pituitary, MEN1 gene), MEN-2A (medullary thyroid + phaeochromocytoma + parathyroid, RET gene), familial isolated hyperparathyroidism, hyperparathyroidism-jaw tumour syndrome. Genetic testing if young (<40), family history, or multi-gland disease.

Clinical assessment: calcium (total + ionised), PTH (intact), 24-hour urine calcium (stone risk + rule out familial hypocalciuric hypercalcaemia), 25-OH vitamin D, creatinine (GFR), bone mineral density (DEXA — lumbar, hip, forearm), abdominal imaging (renal stones). Related service: our thyroid surgery programme.

Preoperative localisation is critical for surgical success — inadequate localisation leads to failed primary surgery or unnecessary wide dissection. In modern minimally invasive surgery (MIP) localisation is mandatory.

Ultrasound (US): first line — bedside, no radiation, cheap, depends on experienced surgeon/radiologist. Parathyroid adenoma features: homogeneous hypoechoic mass behind thyroid, increased Doppler vascularity (notably polar feeding vessel), size usually 0.8-2 cm.

US sensitivity: experienced operator 75-85% for single adenoma; lower for multi-gland (30-50%). Ectopic glands (intrathyroidal, retro-oesophageal, mediastinal) not assessable by US.

Tc-99m sestamibi: standard nuclear medicine test. Sestamibi taken up by thyroid + parathyroid; thyroid washes out faster (15 min), parathyroid (especially adenoma) retains longer (1-3 h). Early + delayed image difference identifies parathyroid adenoma. Modern SPECT or SPECT-CT gives 3D localisation.

Sestamibi sensitivity: single adenoma 80-90%; multi-gland hyperplasia lower (30-50%). Thyroid nodules or thyroiditis cause false positive/negative.

US + sestamibi combination: both positive concordant → surgical success >95%; one positive other negative → 85-90%; both negative → additional imaging.

4D parathyroid CT: contrast CT in time phases (arterial, venous, delayed) — characteristic adenoma enhancement (early uptake, rapid washout). High sensitivity (85-95%), particularly in revision or US/sestamibi-negative.

MRI: debated; useful sometimes (pregnancy — radiation avoidance, ectopic). Sensitivity similar to US/sestamibi.

PET-CT (18F-fluorocholine PET): emerging — useful in complex (recurrent, ectopic, multi-gland) cases. Limited availability in Turkey.

Surgical planning: localised single adenoma (US + sestamibi concordant positive) → MIP (3-4 cm incision, targeted gland); ambiguous or multi-gland suspicion → classical four-gland exploration (5-7 cm incision, all 4 glands evaluated).

Familial/syndromic cases: high multi-gland likelihood — even if localisation does not show all glands, four-gland exploration considered.

Minimally invasive parathyroidectomy (MIP): for single adenoma + positive concordant imaging. 3-4 cm incision (anterior neck), direct access to gland, short duration (45-90 min), low complications, short stay (often same day or 1 night).

MIP techniques: (1) open focal (3-4 cm, classical); (2) video-assisted MIP (VAMP); (3) endoscopic; (4) lateral approach (posterolateral incision). Each with pros/cons; surgeon experience drives outcome.

Intraoperative PTH monitoring (IOPTH): cornerstone of MIP. PTH measured before excision (baseline + induction), then 10-15 minutes after gland removal. Miami criterion: PTH drop ≥50% from baseline → success (no additional disease). Inadequate → additional exploration.

IOPTH advantages: intraoperative decision — convert MIP to four-gland exploration, detect multi-gland disease, intraoperative success check. Disadvantages: rapid lab needed (15-20 min), added cost.

Classical four-gland exploration: for ambiguous localisation, multi-gland suspicion, familial syndrome, revision surgery. 5-7 cm neck incision, all four glands inspected + biopsied. Pathological glands resected.

Subtotal parathyroidectomy: for multi-gland hyperplasia (often MEN-1, familial). 3.5 glands removed, at least 0.5 gland kept (usually lower left — anatomically most stable); reduces postop hypoparathyroidism. Persistent hyperparathyroidism 10-20%.

Total parathyroidectomy + autotransplant: alternative — all 4 glands removed + small fragments autoimplanted into non-dominant forearm or neck muscle. Pros: in case of recurrence, localised forearm easier to monitor. Cons: higher hypoparathyroidism risk if graft fails.

Parathyroid carcinoma: rare (1%), aggressive treatment. Surgery: en bloc resection (parathyroid + ipsilateral thyroid lobe + adjacent tissues + regional lymph nodes). Adjuvant radiotherapy debated. Systemic therapy (cisplatin, dacarbazine) limited efficacy.

Ectopic parathyroid: 5-10% in abnormal location (intrathyroidal, retro-oesophageal, mediastinal, undescended). Mediastinal may need sternotomy; minimally invasive thoracic surgery (VATS) is an alternative.

Revision parathyroidectomy: after failed primary surgery + persistent or recurrent hyperparathyroidism. Scar tissue makes dissection difficult, RLN injury risk higher. Detailed preop localisation (4D CT + sestamibi + selective venous sampling sometimes) mandatory. Surgeon experience is critical — high-volume centre preferred. More detail: thyroidectomy page.

Early postoperative (24-48 hours): calcium and PTH monitoring at 6-12 hours and 24 hours. Transient hypocalcaemia is common — especially with very high preop PTH or long-standing disease ("hungry bone syndrome" — bones suddenly take up calcium).

"Hungry bone syndrome": after severe hyperparathyroidism (high alkaline phosphatase, high PTH, marked bone loss) — calcium rapidly drops below normal (<8 mg/dL), symptomatic hypocalcaemia (paraesthesia — perioral + fingertips, muscle cramp, Chvostek + Trousseau signs, severe — laryngospasm, cardiac arrhythmia). Treatment: IV calcium gluconate (acute), oral calcium (2-4 g/day) + activated vitamin D (calcitriol 0.5-1 µg/day), close monitoring.

Oral calcium + vitamin D prophylaxis: most patients 2-4 weeks. Mild transient hypocalcaemia (8-8.5 mg/dL, asymptomatic) — oral support suffices. Marked (<8 mg/dL or symptomatic) — IV calcium + activated D.

Surgical success criteria: calcium normal ≥6 months, PTH within normal range — cure. Persistent hyperparathyroidism: calcium rises within 6 months — surgical failure or missed gland. Recurrent: hypercalcaemia returns after ≥6 months of normocalcaemia (typically 2-5 years).

Complications: (1) hypoparathyroidism — transient (common, resolves 1-3 months) or permanent (<1% single-gland, 5-10% multi-gland); lifelong calcium + activated D therapy; (2) recurrent laryngeal nerve (RLN) injury — hoarseness (experienced surgeon <1%; bilateral injury rare but life-threatening — respiratory distress, tracheostomy); (3) superior laryngeal nerve (external branch) injury — high-pitched voice hoarseness, issue for professional voice users; (4) bleeding (first 24 h, haematoma — respiratory compromise needs surgical evacuation); (5) infection (rare <1%); (6) scar (usually small incision heals well).

Persistent hyperparathyroidism (postop 6 months): missed gland (commonest — ectopic, anatomic variant), inadequate resection (insufficient in multi-gland), wrong diagnosis (secondary/tertiary). Management: re-localisation (4D CT + sestamibi + sometimes selective venous sampling), revision surgery (high-volume centre).

Recurrent hyperparathyroidism: hypercalcaemia after 6+ months. More common in multi-gland disease (MEN, familial) — remnant gland proliferates. Genetic test + family screening + reoperation (high-experience centre).

Long-term follow-up: first year 3-6 monthly, then annually — calcium, PTH, creatinine, bone mineral density (DEXA 1-2 yearly). Bone loss improves (significant by 4 years), kidney stone risk falls, symptoms (fatigue, depression, memory) improve.

Genetic counselling: in MEN-1 or MEN-2A suspicion or positive family history — genetic test + family screening (calcium + PTH + related hormones). Early diagnosis + treatment improves prognosis.

Calcium-control lifestyle: adequate vitamin D (1000-2000 IU/day), normal calcium diet (1000-1200 mg/day — restriction not recommended), ample fluids (kidney stone prevention), regular exercise (bone health), avoid thiazide diuretics (reduce urine calcium), avoid lithium (PTH stimulation). Related reading: our Istanbul thyroid surgery page.